Get the latest news, insights, and market updates on MYGN (Myriad Genetics, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Myriad (MYGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Myriad (MYGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Nov 4, 2025 - $MYGN
Why Myriad Genetics (MYGN) Stock Is Down Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 19.3% in the morning session after it reported mixed third-quarter results that were overshadowed by a weak earnings outlook. Nov 4, 2025 - $MYGN
Myriad: Q3 Earnings Snapshot
SALT LAKE CITY (AP) — Myriad Genetics Inc. MYGN) on Monday reported a loss of $27.4 million in its third quarter. On a per-share basis, the Salt Lake City-based company said it had a loss of 29 cents. Nov 3, 2025 - $MYGN
Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops
Genetic testing company Myriad Genetics (NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $823 million at the midpoint. Its non-GAAP loss of $0 per share was $0.01 above analysts’ consensus estimates. Nov 3, 2025 - $MYGN
Myriad Genetics (MYGN) Reports Break-Even Earnings for Q3
Myriad (MYGN) delivered earnings and revenue surprises of +100.00% and +0.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 3, 2025 - $MYGN
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
Highlights Third quarter 2025 revenue of $205.7 million decreased by 4% year-over-year but was flat when excluding previously discussed headwinds1 of $8.1 million, consistent with management expectations.Third quarter 2025 hereditary cancer testing revenue and volume grew 3% and 11% year-over-year, respectively. Third quarter 2025 gross margin was 69.9%. Third quarter 2025 GAAP net loss of $27.4 million, or $0.29 per share, while adjusted EPS was $0.00. Third quarter 2025 adjusted EBITDA was $10 Nov 3, 2025 - $MYGN
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple